Small-Molecule Parkinson's Disease Kinase Inhibitor LRRK2-in-1 Demonstrates Potent Anti-Cancer Activity Through Inhibition of DCLK1

被引：0
|
作者：
Weygant, Nathaniel
Qu, Dongfeng
Berry, William L.
May, Randal
Chandrakesan, Parthasarathy
Owen, Daniel
Ali, Naushad
Janknecht, Ralf
Sureban, Sripathi M.
Houchen, Courtney W.
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1929
引用
收藏
页码：S694 / S694
页数：1
相关论文
共 46 条
  • [21] ZH-4B, a small molecule compound isolated from a traditional Chinese medicine Shiraia bambusicola, is potent receptor tyrosine kinase inhibitor with significant anti-cancer activity.
    Zhang, YX
    Chen, Y
    Guo, XN
    Zhang, XW
    Lin, LP
    Zhao, WM
    Ding, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6112S - 6112S
  • [22] Optimization of the anti-cancer activity of the phosphatidylinositol-3 kinase pathway inhibitor PITENIN-1: switching thiourea with 1,2,3-triazole
    Kommagalla, Yadagiri
    Cornea, Sinziana
    Riehle, Robert
    Torchilin, Vladimir
    Degterev, Alexei
    Ramana, Chepuri V.
    MEDCHEMCOMM, 2014, 5 (09) : 1359 - 1363
  • [23] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
    Cirstea, D.
    Hideshima, T.
    Santo, L.
    Eda, H.
    Mishima, Y.
    Nemani, N.
    Hu, Y.
    Mimura, N.
    Cottini, F.
    Gorgun, G.
    Ohguchi, H.
    Suzuki, R.
    Loferer, H.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N.
    LEUKEMIA, 2013, 27 (12) : 2366 - 2375
  • [24] MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer
    Kim, Ah-Young
    Yoon, Yi Na
    Leem, Jiyeon
    Lee, Jee-Young
    Jung, Kwan-Young
    Kang, Minsung
    Ahn, Jiyeon
    Hwang, Sang-Gu
    Oh, Jeong Su
    Kim, Jae-Sung
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [25] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
    D Cirstea
    T Hideshima
    L Santo
    H Eda
    Y Mishima
    N Nemani
    Y Hu
    N Mimura
    F Cottini
    G Gorgun
    H Ohguchi
    R Suzuki
    H Loferer
    N C Munshi
    K C Anderson
    N Raje
    Leukemia, 2013, 27 : 2366 - 2375
  • [26] LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations
    Ohta, Etsuro
    Kawakami, Fumitaka
    Kubo, Makoto
    Obata, Fumiya
    FEBS LETTERS, 2011, 585 (14) : 2165 - 2170
  • [27] LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease
    Bonello, Fiona
    Hassoun, Sidi-Mohamed
    Mouton-Liger, Francois
    Shin, Yea Seul
    Muscat, Adeline
    Tesson, Christelle
    Lesage, Suzanne
    Beart, Philip M.
    Brice, Alexis
    Krupp, Johannes
    Corvol, Jean-Christophe
    Corti, Olga
    HUMAN MOLECULAR GENETICS, 2019, 28 (10) : 1645 - 1660
  • [28] LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations
    Ohta, E.
    Kawakami, F.
    Kubo, M.
    Obata, F.
    JOURNAL OF NEUROCHEMISTRY, 2012, 123 : 104 - 104
  • [29] LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations
    Ohta, E.
    Kawakami, F.
    Kubo, M.
    Obata, F.
    FEBS JOURNAL, 2012, 279 : 374 - 374
  • [30] NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models
    Eskander, Ramez N.
    Monk, Bradley J.
    Slomovitz, Brian M.
    Poradosu, Enrique
    Woods, Allison
    Shemesh, Shay
    Clarke, Paul
    Poele, Robert Te
    Powers, Marissa
    Workman, Paul
    Westin, Shannon N.
    CLINICAL CANCER RESEARCH, 2024, 30 (05)
12345